Microbion is a clinical stage biotechnology company dedicated to the development of its proprietary antimicrobial, anti-biofilm family of compounds as therapeutic agents for the treatment of infectious diseases, including those caused by antibiotic-resistant bacteria. Our lead drug candidate, pravibismane, is the first in a new class of anti-infectives. We have successfully completed three Phase 1 clinical studies to evaluate the safety of a topical/local formulation of pravibismane (MBN-101) in healthy volunteers. Subsequently, two additional clinical studies have been completed: a Phase 2a clinical study to evaluate the safety and efficacy of MBN-101 for the treatment of post-surgical orthopedic device-associated infections and a Phase 1b study to assess safety and preliminary efficacy of MBN-101 for treatment of moderate-to-severe diabetic foot ulcer (DFI) infections. The pre-clinical program for development of an inhaled formulation of pravibismane for treatment of pulmonary infections will be completed by mid-2021. Phase 1 clinical studies in healthy volunteers are planned to begin in late 2021/early 2022. The FDA has granted Qualified Infectious Disease Product (QIDP) and Fast Track designations for treatment of orthopedic device related and moderate-to-severe DFI infections, as well as Orphan Drug, QIDP and Fast Track designations for the management of CF-related lung infections.